SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

SAN

88.23

+0.88%↑

MRK1

114.95

-0.39%↓

SHL.DE

46.57

+0.34%↑

ARGX

515.4

+0.98%↑

FRE

44.24

+0.07%↑

Search

Pharma Mar SA

Cerrado

84.6 -7.74

Resumen

Variación precio

24h

Actual

Mínimo

83

Máximo

84.9

Métricas clave

By Trading Economics

Ingresos

-13M

-3.9M

Ventas

-9.5M

39M

P/B

Media del Sector

78.186

51.198

BPA

-0.22

Rentabilidad por dividendo

0.91

Margen de beneficios

-10.047

Empleados

500

EBITDA

-16M

-1.1M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+18.61% upside

Dividendos

By Dow Jones

Rentabilidad por dividendo

Media del Sector

0.91%

2.40%

Próximas Ganancias

29 jul 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

141M

1.5B

Apertura anterior

92.34

Cierre anterior

84.6

Puntuación técnica

By Trading Central

Confianza

Bearish Evidence

Pharma Mar SA Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

6 jun 2025, 14:31 UTC

Ganancias

New York State Retirement Fund Posts 5.84% Annual Investment Return

6 jun 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 20:50 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 20:33 UTC

Ganancias

These Stocks Moved the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 19:36 UTC

Charlas de Mercado

Oil Futures Post Solid Weekly Gains -- Market Talk

6 jun 2025, 19:28 UTC

Charlas de Mercado

U.S. Natural Gas Futures Rise on Demand Expectations -- Market Talk

6 jun 2025, 18:46 UTC

Charlas de Mercado

Gold Faced With Tariff Uncertainty Offset by ETF Withdrawals -- Market Talk

6 jun 2025, 18:02 UTC

Charlas de Mercado

U.S. Oil Rig Count Continues to Decline -- Market Talk

6 jun 2025, 16:35 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:34 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, DJT, Broadcom, Circle, Lululemon, Docusign, Quanex, Braze, and More -- Barrons.com

6 jun 2025, 16:21 UTC

Charlas de Mercado

Canadian Unemployment Set to Continue Feel Trade War Pressures -- Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Auto & Transport Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

6 jun 2025, 16:20 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

6 jun 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

6 jun 2025, 16:07 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

6 jun 2025, 16:07 UTC

Charlas de Mercado

Base Metal Prices Slide But Copper Set to End Week Higher -- Market Talk

6 jun 2025, 15:53 UTC

Charlas de Mercado

Mexican Inflation Seen Rising in May -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Dollar's Boost From U.S. Jobs Data Could Be Limited -- Market Talk

6 jun 2025, 15:36 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 15:33 UTC

Charlas de Mercado

Gold Futures Slide After Jobs Data Surprises to Upside -- Market Talk

6 jun 2025, 15:16 UTC

Charlas de Mercado

Tesla Showing Signs of Weakness in Key Regions -- Market Talk

6 jun 2025, 15:05 UTC

Charlas de Mercado

Silver at its Highest In Nearly 15 Years -- Market Talk

6 jun 2025, 14:35 UTC

Charlas de Mercado

Weakening Canadian Job Market Seen Keeping BoC in Easing Mode -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Bitcoin Rises After Above-Forecast U.S. Jobs Data -- Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

6 jun 2025, 14:28 UTC

Charlas de Mercado

Canada's Job Market Weakens But Not Seen Collapsing -- Market Talk

6 jun 2025, 14:15 UTC

Charlas de Mercado

Oil Rises on U.S.-China Talks Optimism -- Market Talk

6 jun 2025, 14:12 UTC

Ganancias

Palantir and Super Micro Computer Stocks Rise as Broadcom Posts Strong AI Revenue -- Barrons.com

6 jun 2025, 14:09 UTC

Ganancias

Broadcom, the $1 Trillion Stock You Shouldn't Ignore, Makes AI Investment Case -- Barrons.com

Comparación entre iguales

Cambio de precio

Pharma Mar SA previsión

Precio Objetivo

By TipRanks

18.61% repunte

Estimación a 12 Meses

Media 108.999 EUR  18.61%

Máximo 110 EUR

Mínimo 108 EUR

De acuerdo con 2 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Pharma Mar SA Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

2 ratings

2

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

72.75 / 74.3Soporte y Resistencia

Corto Plazo

Bearish Evidence

Medio plazo

Strong Bearish Evidence

Largo Plazo

Bullish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Pharma Mar SA

Pharma Mar, S.A., a biopharmaceutical company, engages in the research, development, production, and commercialization of bio-active principles for the use in oncology in Spain, Italy, Germany, Ireland, France, rest of the European Union, the United States, and internationally. The company operates through Oncology and RNA Interference segments. It develops and commercializes Yondelis for the treatment of soft tissue sarcoma and for ovarian cancer; Aplidin for treating R/R multiple myeloma; and Zepzelca to treat patients with small cell lung cancer. The company develops Ecubectedin (PM14), which is in phase II clinical trials for the treatment of solid tumors, as well as in Phase I clinical trials for the treatment of soft tissue sarcoma and prostate cancer; PM534 that is Phase I clinical trials for treating solid tumors; PM54, which is in Phase I clinical trials for the treatment of solid tumors; SYL1801 that is in phase II clinical trials for treating macular degeneration; SYL116011, which is in preclinical studies for the treatment of ocular allergies; and SYL A and B that is in investigational studies to treat retinitis pigmentosa. In addition, it engages in the research, development, production, and sale of products with therapeutic activity based on reducing or silencing gene expression. Pharma Mar, S.A. was incorporated in 1986 and is based in Madrid, Spain.